192 related articles for article (PubMed ID: 29422778)
1. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US.
Zafari Z; Sadatsafavi M; Mark FitzGerald J;
Cost Eff Resour Alloc; 2018; 16():3. PubMed ID: 29422778
[TBL] [Abstract][Full Text] [Related]
2. Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma.
Buendia JA; Guerrero Patiño D; Cossio-Giraldo YE
J Asthma; 2022 Oct; 59(10):2016-2023. PubMed ID: 34551659
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of tiotropium in patients with severe asthma.
Buendía JA; Patiño DG
Cost Eff Resour Alloc; 2024 Jan; 22(1):4. PubMed ID: 38238836
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium for children and adolescents with severe asthma.
Antonio Buendía J; Patiño DG
J Asthma; 2023 May; 60(5):1009-1015. PubMed ID: 36047659
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists.
Willson J; Bateman ED; Pavord I; Lloyd A; Krivasi T; Esser D
Appl Health Econ Health Policy; 2014 Aug; 12(4):447-59. PubMed ID: 24974107
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of azithromycin in patients with severe asthma.
Buendía JA; Patiño DG; Feliciano-Alfonso JE
J Asthma; 2022 Oct; 59(10):2008-2015. PubMed ID: 34516322
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
11. Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma.
Buendía JA; Patiño DG
BMC Pulm Med; 2021 Dec; 21(1):398. PubMed ID: 34865635
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence.
Igarashi A; Kaur H; Choubey A; Popli A; Muthukumar M; Yoshisue H; Funakubo M; Ohta K
Value Health Reg Issues; 2022; 27():41-48. PubMed ID: 34784547
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
Han S; Kim S; Kim H; Suh HS
Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
[No Abstract] [Full Text] [Related]
14. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
Dewilde S; Turk F; Tambour M; Sandström T
Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
[TBL] [Abstract][Full Text] [Related]
15. Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2-agonist in real-world patients with asthma.
Chipps B; Mosnaim G; Mathur SK; Shaikh A; Khoury S; Gopalan G; Palli SR; Lamerato L; Casciano J; Dotiwala Z; Settipane R
Allergy Asthma Proc; 2020 Jul; 41(4):248-255. PubMed ID: 32414426
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
Brown R; Turk F; Dale P; Bousquet J
Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β
Buhl R; FitzGerald JM; Busse WW
Respir Med; 2018 Oct; 143():82-90. PubMed ID: 30261998
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy.
Altawalbeh SM; Thorpe JM; Thorpe CT; Smith KJ
Value Health; 2016; 19(5):537-43. PubMed ID: 27565270
[TBL] [Abstract][Full Text] [Related]
19. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data.
Hong SH; Cho JY; Kim TB; Lee EK; Kwon SH; Shin JY
J Allergy Clin Immunol Pract; 2021 May; 9(5):1939-1947.e7. PubMed ID: 33307277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
